Description: Vivek Ramaswamy got a pretty special present for his 32nd birthday in August: $1.1 billion in funding from SoftBank and other investors for the audacious biopharmaceutical firm he founded and leads, Roivant Sciences.
Date: Sep 21, 2017
Questions for discussion:
- What is so unique about this financial structuring?
- Why does it appeal to lenders?
- How does it impact risk?